Editorial
Venlafaxine: the yin and yang of antidepressants? Journal of Psychopharmacology 9(3) (1995) [205] [206] @1995 British Association for Psychopharmacology Venlafaxine is a new antidepressant that has recently been launched in the UK and some other European countries and which has been available in the US since mid 1994. It is a chemical moiety that is distinct from previous antidepressants and has a pharmacology that appears to offer some novelty of action. Specifically, venlafaxine is a serotonin and noradrenaline uptake blocker that has a very high separation of these actions from unwanted interactions with other receptor systems, such as the cholinergic muscarinic, which bedevil the older mixed uptake blockers, the tricyclic antidepressants. In human brain tissue the K,s of venlafaxine for blockade of the 5-HT and noradrenaline uptake sites are -40 and 210 nM respectively (Bolden-Watson and Richelson, 1993), whereas its lC50S for inhibiting cholinergic, histaminergic and a,-adrenoceptors are in the micromolar range (Cusack, Nelson and Richelson, 1994) . As predicted from these findings, venlafaxine performs better than older tricyclic antidepressants in terms of side effect severity (Shrivastava et al., 1994) and has a profile of adverse effects very similar to the selective serotonin re-uptake inhibitors (SSRIs). The only common side effect is nausea, which appears early in treatment, often after the first dose, and generally remits in about a week. This would appear to be a direct consequence of 5-HT uptake blockade as it is found with all SSRIs (and many other antidepressants) and is probably caused by stimulation of vagal 5-HT3 receptors (Bailey et al., 1995) .
What role for noradrenaline?
The key psychopharmacological question with venlafaxine is what benefit derives from the concurrent blockade of noradrenaline with that of 5-HT? There are theoretical grounds for expecting additional efficacy, either in magnitude of clinical effect or in terms of the percentage of patients who might respond. There is a great deal of evidence that increasing brain noradrenaline function is antidepressant; desipramine and lofepramine for instance are selective noradrenaline uptake blockers with proven efficacy. Increasing noradrenaline availability by other means, e.g. pre-synaptic a2-adrenoceptor antagonism with mianserin, mirtazepine or idazoxan (Potter et al., 1995) relieves depression. Electroconvulsive therapy (ECT), the best treatment of severe depression, markedly increases brain noradrenaline release (Thomas, Nutt and Holman, 1992a) . It has been suggested that the early onset of antidepressant effects with ECT is due, in part, to increased monoamine function. This is found to occur before the changes in 5-HT function (Nutt, Green and Grahame-Smith, 1980; Heal et al., 1981) .
Moreover, the combination of an SSRI with a noradrenaline uptake blocker has been shown to more rapidly desensitise brain /3-adrenoceptors, presumably secondary to increased synaptic noradrenaline release (Baron et al., 1988) .
Exciting data which show that the use of high dose venlafaxine in in-patients produces a rapid antidepressant effect are consistent with these pre-clinical findings. This placebo-controlled study found a clinically relevant effect (4-point reduction on the MADRS scale) within 1 week (Guelfi et al., 1995) . If such differences could be demonstrated against active comparators then venlafaxine would represent a significant advance in the treatment of severe depression that would have real gains in terms of patient safety and hospital costs.
Is venlafaxine more effective than SSRIs in the longer term? At least one study has suggested that it might be. A comparison with fluoxetine revealed significantly greater reductions in depression in the venlafaxine group by week 6 (Clerc, Ruimy and Verdeau-Pailles, 1994) . This may represent an additive effect of the two transmitters as has previously been suggested by combination therapies with SSRIs and noradrenaline uptake blockers (Nelson et al., 1991; Seth et al., 1992) .
Unanswered questions
So far so good. However, in addition to validating the positive findings with venlafaxine, more research needs to be done to establish the claim that any special properties of this drug reflect the additional noradrenergic component. Some of the currently used SSRIs have ratios of 5-HT/noradrenaline uptake blockade that are not dissimilar to those of venlafaxine (Preskorn, 1994) . At present there is no clinical and very little pre-clinical evidence for venlafaxine affecting brain noradrenaline systems in a fashion that is significantly different from that of the SSRIs, some of which can also increase brain noradrenaline function in the longer term (Thomas, Nutt and Holman, 1992b) .
Some of the side effects of venlafaxine, such as tremor and mildly increased supine blood pressure in some patients, are consistent with increased peripheral noradrenaline activity, but this has not been formally measured. There are a number of means by which alterations in noradrenaline uptake can be assessed in humans. These include reduction in plasma MHPG and DHPG; increase in plasma melatonin; blockade of the tyramine actions on blood pressure or the pupil; increase in noradrenaline on standing; raised level of [ 3H ] noradrenaline spillover; increase in pressor responses to a2-adrenoceptor antagonists and reduced responses to az-adrenoceptor agonists.
It would be of interest to explore one or more of these measures to determine whether venlafaxine really does have a significant action on noradrenergic systems at clinical doses.
If venlafaxine can be shown to have a meaningful action on both 5-HT and noradrenaline function and this differentiates it from the SSRIs then it would represent a real advance in the psychopharmacology of depression. Other compounds with ratios of 5-HT/noradrenaline uptake near to parity are also under development; these include nefazodone, duloxetine and minalcipram. Similar questions over the relative importance of serotonin and noradrenaline in their actions remain to be resolved.
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